DYN — Dyne Therapeutics Share News
0.000.00%
Last trade - 00:00Dyne Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation For DYNE-251 In Duchenne Muscular Dystrophy
U.S. RESEARCH ROUNDUP-Darden Restaurants, Nike, Optinose
Brief: Dyne Therapeutics Announces Appointment of Erick J. Lucera As Chief Financial Officer
Dyne Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Dyne Therapeutics Receives FDA Fast Track Designation For Dyne-101
U.S. RESEARCH ROUNDUP-Allstate, Mongodb, Primerica
U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart
Dyne Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Dyne Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Teck Resources, Nasdaq, T-Mobile
U.S. STOCKS ON THE MOVE-United Parcel Service, Boeing
U.S. STOCKS ON THE MOVE-Tesla, Dow, Harley-Davidson
Dyne Therapeutics falls as J.P. Morgan downgrades to 'neutral'
U.S. STOCKS ON THE MOVE-Dyne Therapeutics, Maxeon Solar, chip stocks
U.S. STOCKS ON THE MOVE-Walgreens, Copper miners, Simon Property
Dyne Therapeutics slumps on safety concerns over drug trial, management changes
Brief: Dyne Therapeutics Announces Key Leadership Appointments
Brief: Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251